Yansong Pu

Area of research

Hepatology · Epidemiology

Research interest

Research topics from publications: Luteolin exerts an anticancer effect on gastric cancer cells through multiple signaling pathways and regulating miRNAs; Colorectal Cancer: An Overview; LncRNA IGFL2‐AS1 functions as a ceRNA in regulating ARPP19 through competitive binding to miR‐802 in gastric cancer; Clinical significance of controlling nutritional status score (CONUT) in evaluating outcome of postoperative patients with gastric cancer; LncRNA LINC02253 activates KRT18/MAPK/ERK pathway by mediating N6-methyladenosine modification of KRT18 mRNA in gastric cancer; C1222C Deletion in Exon 8 of ABL1 Is Involved in Carcinogenesis and Cell Cycle Control of Colorectal Cancer Through IRS1/PI3K/Akt Pathway; IL-17A up-regulates expression of endothelial tissue factor in liver cirrhosis via the ROS/p38 signal pathway; JHDM1D-AS1 aggravates the development of gastric cancer through miR-450a-2-3p-PRAF2 axis; LRP4 promotes migration and invasion of gastric cancer under the regulation of microRNA-140-5p; RP11-874J12.4, a novel lncRNA, confers chemoresistance in human gastric cancer cells by sponging miR-3972 and upregulating SSR2 expression. Representative work: Accumulating studies confirmed that luteolin, a common dietary flavonoid which is widely distributed in plants and has diverse beneficial biological function, including anti-oxidant, anti-inflammation and anticancer properties. However, the detail mechanisms of luteolin on GC are poorly understood. Here, we investigated the anticancer effect of luteolin in GC cells in vitro and in vivo. Luteolin reduced the cell viability in a time and dose-dependent manner. Luteolin significantly inhibited cell cycle progress, colony formation, proliferation, migration, invasion and promoted apoptosis in vitro and in vivo. Luteolin also regulated these biological effects associated regulators. Mechanically, Colorectal cancer is a multifactorial disease. It is the third most frequently diagnosed cancer, and the second most common cause of cancer-related deaths worldwide. The etiology of colorectal cancer remains unclear. Although early diagnosis can significantly improve the prognosis, colorectal cancer patients often have no typical clinical manifestations, or display only non-specific signs in the early stage, resulting in a low early diagnosis rate. Multiple treatment modalities, depending on the stage of the tumor and patient

Looking for a research collaborator?

Search millions of scientists by field, institution, impact, and funding status — see their work, find their email, and reach out directly.